Research programme: covalent inhibitors - Aurigene

Drug Profile

Research programme: covalent inhibitors - Aurigene

Alternative Names: CDK7 inhibitor; KRAS inhibitor; MALT-1 inhibitor

Latest Information Update: 17 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CD7 antigen inhibitors; Cyclin-dependent kinase inhibitors; KRAS protein inhibitors; MALT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Apr 2016 Research programme: covalent inhibitors - Aurigene is available for licensing as of 15 Apr 2016
  • 15 Apr 2016 Preclinical trials in Cancer in India (unspecified route) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top